Somatorelin is 29 amino acid analogue of human growth hormone-releasing hormone used as a diagnostic agent for determining growth hormone deficiency. Growth-hormone-releasing hormone (GHRH, somatoliberin) is the hypothalamic peptide hormone that specifically stimulates synthesis and release of growth hormone (GH, somatotropin) by somatotrope cells of the anterior pituitary gland. The hypothalamic hormone growth hormone (GH)-releasing hormone (GHRH) acts on specific GHRH receptors (GHRH-R) in the anterior pituitary gland to stimulate the synthesis and secretion of GH and to promote somatotrope expansion. Somatorelin is applied to determine the somatotropic function of the anterior pituitary gland in cases of suspected growth hormone deficiency. The test distinguishes between pituitary and hypothalamic disorders but is not suitable as a screening test for growth hormone deficiencies. Somatorelin has been used in trials studying the treatment of Aging, Elderly, Sleep Disorders, Hormone Deficiency, and Mild Cognitive Impairment.

Elcatonin is a physio-chemically stable calcitonin derivative in which the disulfide bond between cysteine residues at positions 1 and 7 of eel calcitonin has been replaced by an ethylene bond. The primary pharmacological effect of Elcatonin is its activity at specific osteoclast receptors, resulting in diminished osteoclast activity at extremely low concentrations. Elcatonin inhibits the bones autolysis and renal calcium, phosphorus, and sodium reabsorption thus keeps blood calcium at a normal level. In clinical settings, once-weekly intramuscular injection of elcatonin has been shown to significantly increase bone mineral density within 6 months and to alleviate post-fracture pain and improve Quality of life in osteoporosis

Thymalfasin, a synthetic version of thymosin-α-1, a polypeptide (protein fragment) was being developed by SciClone Pharmaceuticals for the treatment of liver disease. SciClone developed and launched Thymalfasin, under the trade name Zadaxin, for the treatment of hepatitis B and hepatitis C virus infections. The drug is also being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS and malignant melanoma. Thymalfasin exerts a dual action against infections: immune modulating and direct-acting effect. Thymalfasin exerts its immune-modulating activity through the interaction with Toll-like receptors (TLR), a group of proteins involved in the regulation of innate immunity, and in particular with TLR9 and TLR2 on dendritic cells (DCs) and precursor T-cells. Thymalfasin is also able to prevent a pro-inflammatory cytokine storm and possibly autoimmune events. Regarding direct-acting effects, Thymalfasin has been shown to increase the expression of MHC Class I and II, which are important for the antigen presentation and recognition by the immune system of the virally infected cells. v has also been shown to directly inhibit the in vitro growth of virally infected and cancer cells. Thymalfasin is not approved by the FDA but it is widely used in China and some other countries.